Senseonics stock trades at EUR 8.35 as Freedom study draws focus
Published on 10/30/2026 at 19:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSBusiness Update And Market Context
- Senseonics launched a first-in-human study for Freedom, a continuous glucose monitoring system designed without an on-body component.
- The company develops implantable glucose monitoring systems for people with diabetes.
Senseonics said on October 26, 2026, that it had initiated a first-in-human study of Freedom, a continuous glucose monitoring system designed without an on-body component. The announcement is available in the Senseonics investor relations release.
Freedom Study Expands Product Pipeline
Freedom is intended to extend Senseonics' focus on long-term, implantable glucose monitoring. The company says its Eversense and Eversense XL systems use an under-the-skin sensor, a removable and rechargeable transmitter, and an app for diabetes monitoring.
Senseonics stock traded at 8.35 euros on Lang & Schwarz at 19:09 Berlin time on Friday, October 30, 2026.
Investors can follow the real-time quote of Senseonics stock for the latest market indication.
Senseonics Holdings Stock Facts
- Company: Senseonics Holdings, Inc.
- ISIN: US81727U3032
- Ticker: SENS
- Trading venue: Lang & Schwarz
- Quote: 8.35 euros on October 30, 2026, at 19:09 Berlin time
US equities are commonly assessed against the S&P 500.
More developments can be found in more news and analyses on Senseonics stock.
